Programme

 

Go directly to a day's programme
Thursday | Friday | Saturday

 

 

Tuesday 25 February 2014

 

15.00 – 18.00 Pre-Meeting Workshop
 

Aspergillus Speciation in the 21st Century –

Implications for Laboratory and Clinical Practice

Open to 20 – 30 doctors, scientists or clinical microbiologists or pharmacists involved in diagnosis, prophylaxis and treatment of invasive fungal infections
Lead by Manuel Cuenca-Estrella, MD PhD


Please click here for more detailed information or to register

 

Wednesday 26 February 2014

 

09.00 – 18.15 Pre-Meeting Workshop
 

Aspergillus Speciation in the 21st Century –

Implications for Laboratory and Clinical Practice

Open to 20 – 30 doctors, scientists or clinical microbiologists or pharmacists involved in diagnosis, prophylaxis and treatment of invasive fungal infections
Lead by Manuel Cuenca-Estrella, MD PhD


Please click here for more detailed information or to register

 

Thursday 27 February 2014 – Day 1

 

Special Morning Session: Meet the Professor

 

08.00 – 09.00

PK/PD of anti-Aspergillus triazoles
William Hope, BMBS FRACP FRCPA PhD

   
08.00 – 09.00

Aspergillus cell wall and biofilm
Anne Beauvais, PhD


   
09.00 – 09.10

Opening Remarks
David W. Denning, FMedSci

 

 

Session 1: Factors affecting Aspergillus Pathogenesis

Moderators: Jean-Paul Latgé, PhD & David S. Askew, PhD

 

09.10 – 09.35 

Hyphal growth and septation
Praveen Rao Juvvadi, PhD

   
09.35 – 10.00  Zinc homeostasis and its significance for Aspergillus fumigatus virulence
José Antonio Calera, PhD
   
10.00 – 10.15  Modification of exopolysaccharide composition can increase the virulence of non-pathogenic Aspergillus species
Mark J. Lee, MSc
   
10.15 – 10.30  The ZrfC alkaline zinc transporter is required for Aspergillus fumigatus virulence and its growth in the presence of the Zn/Mn-chelating protein calprotectin
Jorge Amich, PhD
   
10.30 – 10.55 The molecular mechanism of Aspergillus adhesion – lessons from bacteria
Donald Sheppard, MD
   
10.55 – 11.05  Discussion


   
11.05 – 11.35 Coffee Break

 

Session 2: New Anti-Aspergillus Drug Targets

Moderators: William J. Steinbach, MD & José Maria Aguado, MD PhD

 

11.35 – 12.00

New agents for aspergillosis: development pathways and economic pull
John H. Rex, MD

12.00 – 12.15 Study of the MtfA transcription factor in the opportunistic fungal pathogen Aspergillus fumigatus
Timothy Smith
   
12.15 – 12.30 In vivo manipulation of lung oxygen content to reduce fungal growth during murine invasive pulmonary aspergillosis
Robert A. Cramer, PhD
 

12.30 – 13.00 Lunch

     

Session 3: Difficult Clinical Cases

 

13.00 – 14.45 Poster Session 1
   
13.45 – 14.45

Difficult clinical cases
José Maria Aguado, MD PhD & Dimitrios P. Kontoyiannis, MD

 

Session 4: Antifungal Resistance

Moderators: Cornelia Lass-Flörl, MD PhD & Manuel Cuenca-Estrella, MD PhD

 

14.45 – 15.10 Aspergillus virulence profiles and azole resistance in Aspergillus fumigatus – clinical isolate screening, culture selection and genetics
Liliana Losada, PhD
   
15.10 – 15.25 A novel transcriptional regulator AtrR of Aspergillus fumigatus is required for azole resistance, hypoxia growth, and expression of ABC transporter gene cdr1B
Daisuke Hagiwara, PhD
   
15.25 – 15.40 Voriconazole resistant Aspergillus fumigatus carrying
TR46/Y121F/T289A mutation from the Indian environment
Cheshta Sharma
   
15.40 – 16.00

Agricultural triazole fungicides should be withdrawn – PRO
Katrien Lagrou, PharmD PhD

16.00 – 16.20

Agricultural triazole fungicides should be withdrawn – CON
Bart Fraaije, PhD

16.20 – 16.35 Discussion from the floor and vote
 

   
16.35 – 17.05 Coffee Break

 

Session 5: Therapeutics

Moderators: Dimitrios P. Kontoyiannis, MD & Alessandro Pasqualotto, MD PhD

 

17.05 – 17.30 Combination therapy update
Johan Maertens, MD PhD
   
17.30 – 17.55 Posaconazole breakthroughs
Jutta Auberger, MD
   
17.55 – 18.10 Identification of Aspergillus fumigatus wall compounds that affect activity and function of human platelets
Cornelia Speth, PhD
   
18.10 – 18.25 Effect of ghrelin for prevention in murine invasive pulmonary aspergillosis model
Kazuaki Takeda, MD
   
18.25 – 18.50

The burden and distinctive character of ABPA in India
Ritesh Agarwal, MD DM

 

19.00 – 19.30 Welcome Reception

 

Astellas Satellite Symposium:
Advancing Outcomes and Overcoming Adversities in Invasive Aspergillosis

 

19.30 – 19.40 Welcome and introductions Clinical perspectives
David W. Denning, FMedSci
   
19.40 – 20.00 Treating invasive aspergillosis: strengths and limitations
Johan Maertens, MD PhD
   
20.00 – 20.20 Ongoing challenges: drug interactions and tolerability
Russell Lewis, PharmD FCCP BCPS
   
20.20 – 20.30

Q&A followed by closing comments
David W. Denning, FMedSci

Friday 28 February 2013 – Day 2

 

Special Morning Session: Meet the Professor

 

08.00 – 09.00

Aspergillus immunology update
Luigina Romani, MD PhD

   
08.00 – 09.00

Aspergillus, sex and recombination
Janos Varga, PhD

   
   
09.00 – 09.10

Announcement of Scholarship Winners
David A. Stevens, MD

  

 

Session 6: Immunopathology

Moderators: Luigina Romani, MD PhD & David A. Stevens, MD

 

09.10 – 09.35

Fungal role in pulmonary microbiome: Pseudomonas-Aspergillus interaction
Richard B. Moss, MD

   
09.35 – 10.00 Targeting Aspergillus fumigatus virulence factors in a mouse model of corneal infection
Eric Pearlman, PhD
   
10.00 – 10.25

Immunoevasive Aspergillus virulence factors
Sanjay H. Chotirmall, MD PhD

10.25 – 10.40 Noncanonical autophagy is a target of fungal cell wall melanin
Tonia Akoumianaki, PhD
   
10.40 – 10.55 Aspergillus fumigatus CalA binds to β1 integrins and mediates host cell invasion and virulence
Hong Liu, PhD
   
10.55 – 11.05 Discussion
 

   
11.05 – 11.35 Coffee Break



Session 7: Diagnostics

Moderators: Juan Luis Rodriquez Tuldela, MD PhD & Ritesh Agarwal, MD DM

 

11.35 – 12.00

Culture and sensitization in asthma, CF and COPD – what does it tell us?
Catherine Pashley, PhD

12.00 – 12.25

MALDI-TOF – any use for Aspergilli?
Maurizio Sanguinetti, MD

12.25 – 12.40 Diagnosis of invasive aspergillosis (IA) in HIV infected patients
Blandine Denis, MD
   
12.40 – 12.55 Direct detection of an Aspergillus fumigatus-specific breath volatile organic metabolite profile for the diagnosis of invasive aspergillosis
Sophia Koo, MD
   
12.55 – 13.20 Recombinant Abs in IA diagnostics
Michael D. Gunn, MD
   
13.20 – 13.30 Discussion
   
 

13.30 – 14.30 Lunch
   
   
14.30 CONFERENCE SOCIAL EVENT:
Tour and Palace Visit, followed by Dinner
   

Saturday 1 March 2014 – Day 3

 

Special Morning Session: Meet the Professor

 

08.00 – 09.00 Protein degradation and virulence in Aspergillus fumigatus
Gerhard H. Braus, PhD
   
   
09.00 – 09.10 NIAID resources and the global research community
Dennis M. Dixon, PhD

 

 

Session 8: Aspergillus Biology

Moderators: Josep Guarro, PhD & Donald Sheppard, MD

 

09.10 – 09.35

Ras pathway and polarized growth
Jarrod R. Fortwendel, PhD

   
09.35 – 10.00

Cell wall and galactosaminogalactan and immunosuppression
Frank van de Veerdonk, MD PhD

10.00 – 10.15 Aspergillus fumigatus – deciphering the role of the chitin synthase families I and II by multiple gene targeting deletion
Vishu K. Aimanianda
   
10.15 – 10.30 Molecular detection of Aspergillus fumigatus and section Fumigati by multiplex real time PCR using ITS and B-tubuline sequences
Jimena V. Fernandez Molina
   
10.30 – 10.55  Imaging and analysing intracellular calcium dynamics in Aspergillus fumigatus in response to environmental stress
Nick D. Read, PhD
   
10.55 – 11.05 Discussion
 

   
11.05 – 11.35  Coffee Break

     

Session 9: Chronic and Allergic Aspergillosis

Moderators: Richard B. Moss, MD & Koichi Izumikawa, MD PhD

 

11.35 – 12.00 Chronic pulmonary aspergillosis (CPA) secondary to tuberculosis and HIV
Iain Page, MB ChB
   
12.00 – 12.15 The temporal sequence of the transition from asthma through allergic bronchopulmonary aspergillosis to chronic pulmonary aspergillosis
David Lowes
   
12.15 – 12.30 Aspergillus lipoxygenase: a novel instigator of asthma
Greg Fischer, BS
   
12.30 – 12.55 Second line therapy for allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS) – how far have we gone?
Livingstone Chishimba, MB ChB MRCP
   
12.55 – 13.05 Discussion
   
 

13.05 – 14.20 Lunch and Poster Session 2

 

Session 10: Immunogenetic Associations

Moderators: Karl V. Clemons, PhD & Emilia Mellado, MD PhD

 

14.20 – 14.45

Genome-wide scan using the Immunochip to identify susceptibility loci for IA
Juan Sainz Pérez, PhD

   
14.45 – 15.10  Functional aspects of IA-linked genetic variants
Agostinho Carvalho, PhD
   
15.10 – 15.25 Differential regulation of the host response to Aspergillus fumigatus by NOD receptors
Mark Gresnigt
   
15.25 – 15.40

Induction of MUC5AC expression to Aspergillus fumigatus in airway epithelial cells and suppressive effects brought about macrolide antibacterial agents
Katsuji Hirano, MD

   
15.40 – 16.05 Genetic factors underlying ABPA
Paul Bowyer, PhD
   

 

Session 11: Clinical and Scientific Future of Early Anti-Aspergillus Agents

Moderators: David W. Denning, FMedSci & John H. Rex, MD

 

16.05 – 16.30 Early clinical studies of novel antifungal agents
Haran Schlamm, MD
   
16.30 – 17.00 Roundtable discussion
   
   
   
   
17.00

Awards for best submitted abstract

Closing remarks
William J. Steinbach, MD

   
   
   
   
17.15 Farewell Drinks and Discussion about AAA 2016
   
Astellas Pharma Europe Ltd are not supporting or funding the social aspects of the congress programme but will be funding the Welcome Reception alongside their symposium

 

Madrid

 

Madrid